Literature DB >> 19416000

Identification of a neck lump as a lymph node metastasis from an occult contralateral papillary microcarcinoma of the thyroid: key role of thyroglobulin assay in the fine-needle aspirate.

Rocco Bruno1, Paolo Giannasio, Rosarita Chiarella, Carmelo Capula, Diego Russo, Sebastiano Filetti, Giuseppe Costante.   

Abstract

BACKGROUND: Thyroglobulin (Tg) assay of material from fine-needle aspiration of neck masses can help distinguish neck masses of thyroid origin from other masses. We describe its utility in a patient with an unusual constellation of findings, a neck lump identified as a lymph node metastasis from a contralateral occult papillary thyroid carcinoma (PTC).
SUMMARY: A 56-year-old woman was referred to our center for evaluation of a 15-mm right lateral cervical neck mass which was strongly hypoechoic, not homogenous and contained several microcalcifications. There was no family history of thyroid disease, the patient was euthyroid and was not taking medications for thyroid disorders. On physical examination the thyroid was slightly enlarged and was normal on ultrasound except for a 1 x 3 mm hypoechoic nodule in the middle of the left lobe. Ultrasound-guided fine-needle aspiration biopsy (FNAB) of the right lateral cervical mass was performed with the Tg concentration of the FNAB washout liquid being >300 ng/mL and the cytology showing lymphoid elements mixed with polymorphous epithelial cells with atypical nuclei, suggesting lymph node metastasis from a cancer of epithelial origin. A lymph node metastasis from a papillary thyroid microcarcinoma (micro-PTC) was the presumptive diagnosis with the preoperative staging being Tx N1b. The patient underwent total thyroidectomy and bilateral lymph node dissection. At pathology, the right cervical mass was confirmed as lymph node metastasis of a PTC, and a unifocal micro-PTC was found in the middle left lobe. The patient was readmitted for a therapeutic (131)I dose (4810 MBq). At the time of (131)I administration, the whole-body scan showed only minimal thyroid bed uptake and serum Tg was <1 ng/mL. She was maintained on l-thyroxine treatment (150 microg/d). Five year later she did not have evidence of recurrent or residual PTC.
CONCLUSIONS: We describe the first case of contralateral lymph node metastasis from a unifocal micro-PTC identified by the detection of high Tg levels in the wash-out liquid of FNAB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416000     DOI: 10.1089/thy.2009.0049

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  5 in total

1.  Ectopic submandibular thyroid tissue with a coexisting normally located multinodular goitre: case report and review of the literature.

Authors:  Eliana Piantanida; Emanuele Compri; Adriana Lai; Valentina Lombardi; Ilaria Dalle Mule; Myriam Gandolfo; Luigi Liparulo; Lorenza Sassi; Gianlorenzo Dionigi; Stefano La Rosa; Nikolaos Papanikolaou; Carlo Neri; Patrizio Marnini; Maria Laura Tanda; Luigi Bartalena
Journal:  BMJ Case Rep       Date:  2009-12-03

2.  Lymph node metastasis from undiagnosed occult papillary thyroid cancer.

Authors:  Antonella Carbone; Pasquale Bellitti; Rocco Bruno
Journal:  Endocrine       Date:  2013-07-11       Impact factor: 3.633

3.  Diagnostic performance of thyroglobulin value in indeterminate range in fine needle aspiration washout fluid from lymph nodes of thyroid cancer.

Authors:  Yu-Mee Sohn; Min Jung Kim; Eun-Kyung Kim; Jin Young Kwak
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

4.  Papillary thyroid microcarcinoma with contralateral lymphatic skip metastasis and breast cancer: A case report.

Authors:  Min Ding; Ya-Hui Kong; Jian-Hua Gu; Rong-Li Xie; Jian Fei
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.337

5.  Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.

Authors:  Tada Kunavisarut; Ipshita Kak; Christina Macmillan; Ranju Ralhan; Paul G Walfish
Journal:  BMC Cancer       Date:  2012-11-15       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.